• antimoustique-fog

    About us

An integrated approach to prevent and sustainably control Aedes-transmitted diseases

The Global Dengue & Aedes-Transmitted Diseases Consortium (GDAC) brings together the Partnership for Dengue Control (PDC), the International Vaccine Institute (IVI), the International Vaccine Access Center (IVAC) at the Johns Hopkins Bloomberg School of Public Health, and the Duke-NUS Medical School in the fight against Aedes-transmitted diseases. The World Health Organization (WHO) is an observer and advises GDAC.

Our Mission

GDAC advises and provides consultation to national and local health agencies in the development and implementation of innovative, targeted and synergistic approaches to prevent and control Aedes-transmitted diseases including dengue, Zika, chikungunya and yellow fever. Our goals are in line with the WHO global strategy and include accelerating innovations in vaccines, therapeutics, vector control, disease surveillance and diagnostics; promoting evidence-based prevention and control strategies nationally and internationally; strengthening advocacy, capacity building and networking.

Supporting the WHO Global Strategy 2012-2020

According to WHO, vector-borne diseases account for more than 17% of all infectious diseases, causing more than 700,000 deaths annually. Zika, dengue, chikungunya, and yellow fever are all transmitted to humans by the Aedes aegypti mosquito, and all but yellow fever have caused pandemics in the 21st century. More than half of the world’s population live in areas where this mosquito species is present. Sustained, integrated mosquito control and vaccines are needed to prevent epidemics of these and other diseases with similar transmission cycles.

GDAC supports activities that contribute to the WHO target of reducing deaths caused by dengue and other Aedes-transmitted diseases and of ultimately eliminating them as a public health burden.

A Wealth of Expertise

GDAC brings a wealth of expertise to the effort to prevent and control Aedes-transmitted diseases. GDAC partners, through the Dengue Vaccine Initiative, have provided independent guidance to countries struggling with outbreaks, convening governments, the scientific community, international and local stakeholders as well as national regulatory authorities to share information. Through PDC, the partners have provided a forum in which scientists from different domains have worked together to devise more effective, integrated and synergistic disease prevention strategies.

GDAC Governance

GDAC is managed by a steering committee chaired by Duane J. Gubler, Emeritus Professor and founding Director of the Emerging Infectious Diseases Program, Duke-NUS Medical School, Singapore. The Director of GDAC is Eng Eong Ooi, Deputy Director and Professor of Emerging Infectious Diseases at the Duke-NUS Medical School. He is also a Professor at the SingHealth Duke-NUS Global Health Institute, and at the National University of Singapore’s Saw Swee Hock School of Public Health, as well as the Department of Microbiology and Immunology, Yong Loo Lin School of Medicine.

At least one representative from each member partner sits on the steering committee. The Chairperson and committee members each have one vote in decision-making. As an observer, WHO is invited to steering committee meetings on an ad hoc basis. Coordination and administrative and logistical support are provided by the GDAC Secretariat and scientific, technical and strategic guidance by the GDAC Technical Advisory Group (TAG). Working groups address specific topics and report to the GCMC.

Duane J. Gubler“The global trends of population growth, Urbanization and globalization have combined to provide the ideal conditions for the emergence and spread of Aedes-transmitted diseases. There is no indication that these trends will reverse anytime soon so we can expect more epidemics in the future unless we can develop effective prevention strategies. GDAC is perfectly suited to help countries develop strategies that will prevent major epidemics”Duane J. Gubler

Ooi Eng Eong“A lot of exciting science on Aedes-transmitted diseases is being done, even at this moment, and some of these new pieces of knowledge are ripe for translation into disease prevention measures. However, any new disease prevention program will need to be adapted to local factors to maximize the likelihood of success. GDAC thus hopes to work with health authorities to implement scientific findings pragmatically to reduce the negative impact of Aedes-transmitted diseases on global health and economies.”Eng Eong Ooi

Member Partners

GDAC brings a wealth of expertise to the effort to prevent and control Aedes-transmitted diseases. GDAC partners, through the Dengue Vaccine Initiative, have provided independent guidance to countries struggling with outbreaks, convening governments, the scientific community, international and local stakeholders as well as national regulatory authorities to share information. Through PDC, the partners have provided a forum in which scientists from different domains have worked together to devise more effective, integrated and synergistic disease prevention strategies.

International Vaccine Institute

The International Vaccine Institute (IVI) is an international organization devoted to developing and introducing new and improved vaccines to protect the world’s poorest people, especially children in developing countries. Established in 1997, IVI operates as an independent international organization under a treaty signed by 35 countries and the World Health Organization. The Institute conducts activities in more than 20 countries of Asia, Africa and Latin America on vaccines against a variety of diseases and develops new and improved vaccines at its headquarters in Seoul, Republic of Korea.

International Vaccine Institute

International Vaccine Access Center

The International Vaccine Access Center (IVAC) aims to accelerate equitable and sustainable access to vaccines through the generation, synthesis, and use of evidence to inform decision making and action. IVAC accomplishes this by drawing upon expertise from the Johns Hopkins Bloomberg School of Public Health faculty and partners. IVAC works to build knowledge about the value of vaccines to help support strong immunization programs through targeted, policy-focused research and practice in areas such as disease burden, cost-effectiveness, vaccine policy, financing, demand forecasting and disease epidemiology.

International Vaccine Access Center

Partnership for Dengue Control Foundation

The Partnership for Dengue Control (PDC) was created in 2013 to spearhead an integrated approach to sustainably control and prevent dengue. As a non-profit foundation, it brings together leading experts in the dengue-prevention community from different fields to address key issues, with an emphasis on combining vector control and vaccination strategies. PDC seeks to build synergies among the many new and innovative tools in the development pipeline. Its unique approach is developed through workshops, multidisciplinary task forces, research agenda, advocacy and other initiatives. Hosted by the Mérieux Foundation, PDC is led by an independent board with Prof. Thomas W. Scott as Chairperson and Prof. Annelies Wilder-Smith as Director.

Partnership for Dengue Control Foundation

Duke-NUS Medical School

The Duke-NUS Medical School (Duke-NUS) was established in 2005 as a strategic collaboration between the Duke University School of Medicine, located in North Carolina, USA, and the National University of Singapore (NUS). Duke-NUS offers a graduate-entry, 4-year MD (Doctor of Medicine) training programme based on the unique Duke model of education, with one year dedicated to independent study and research projects of a basic science or clinical nature. Duke-NUS also offers MD/PhD and PhD programmes. Duke-NUS has five Signature Research Programmes: Cancer and Stem Cell Biology, Neuroscience and Behavioural Disorders, Emerging Infectious Diseases, Cardiovascular and Metabolic Disorders, and Health Services and Systems Research. Duke-NUS and SingHealth have established a strategic partnership in academic medicine that will guide and promote the future of medicine, tapping on and combining the collective strengths of SingHealth’s clinical expertise and Duke-NUS’ biomedical sciences research and medical education capabilities.

Duke-NUS Medical School